123 related articles for article (PubMed ID: 27558389)
1. Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.
Eroukhmanoff J; Castinetti F; Penel N; Salas S
BMC Cancer; 2016 Aug; 16(1):679. PubMed ID: 27558389
[TBL] [Abstract][Full Text] [Related]
2. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
Toubert ME; Vercellino L; Faugeron I; Lussato D; Hindie E; Bousquet G
Thyroid; 2011 Apr; 21(4):451-4. PubMed ID: 21385075
[TBL] [Abstract][Full Text] [Related]
3. (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Schneider TC; Kapiteijn E; van Wezel T; Smit JWA; van der Hoeven JJM; Morreau H
BMC Cancer; 2016 Jan; 16():31. PubMed ID: 26786320
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib-induced severe urticaria in a patient with hepatocellular cancer.
Musri FY; Mutlu H; Kıvrak Salim D; Karakurt Eryılmaz M; Ünal B; Tural D; Şenol Coşkun H
J Oncol Pharm Pract; 2016 Apr; 22(2):350-3. PubMed ID: 25567520
[TBL] [Abstract][Full Text] [Related]
5. Chordoma: a case series and review of the literature.
Alan O; Akin Telli T; Ercelep O; Tanrikulu Simsek E; Basoglu Tuylu T; Mutis A; Hasanov R; Kaya S; Akgül Babacan N; Dane F; Yumuk PF
J Med Case Rep; 2018 Aug; 12(1):239. PubMed ID: 30145982
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C
Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739
[No Abstract] [Full Text] [Related]
7. Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
Prescrire Int; 2016 Feb; 25(168):37. PubMed ID: 27042725
[TBL] [Abstract][Full Text] [Related]
8. Chronic recurrent stress due to panic disorder does not precipitate Graves' disease.
Chiovato L; Marinò M; Perugi G; Fiore E; Montanelli L; Lapi P; Cavaliere R; Ciampi M; Patronelli A; Placidi G; Placidi GF; Cassano GB; Pinchera A
J Endocrinol Invest; 1998 Dec; 21(11):758-64. PubMed ID: 9972676
[TBL] [Abstract][Full Text] [Related]
9. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
10. Hypothyroidism during treatment with tyrosine kinase inhibitors.
Zygulska AL; Krzemieniecki K; Sowa-Staszczak A
Endokrynol Pol; 2012; 63(4):302-6. PubMed ID: 22933166
[TBL] [Abstract][Full Text] [Related]
11. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
12. Imatinib in advanced chordoma: A retrospective case series analysis.
Hindi N; Casali PG; Morosi C; Messina A; Palassini E; Pilotti S; Tamborini E; Radaelli S; Gronchi A; Stacchiotti S
Eur J Cancer; 2015 Nov; 51(17):2609-14. PubMed ID: 26283036
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib: osteonecrosis of the jaw.
Prescrire Int; 2015 Nov; 24(165):269. PubMed ID: 26688904
[No Abstract] [Full Text] [Related]
14. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
15. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
[No Abstract] [Full Text] [Related]
16. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
van Doorn L; Eskens FA; Visser TJ; van der Lugt A; Mathijssen RH; Peeters RP
Thyroid; 2011 Feb; 21(2):197-202. PubMed ID: 21275767
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
18. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
19. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
[TBL] [Abstract][Full Text] [Related]
20. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]